Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial

Dear Editor, Chi et al.1 have updated the second interim analysis of the MAGNITUDE trial assessing niraparib plus abiraterone acetate with prednisone (AAP) for patients with metastatic castration-resistant prostate cancer (mCRPC). Although niraparib plus AAP as the first-line treatment significantly prolonged radiographic progression-free survival, it showed no benefit on overall survival (OS) of patients with… Continue reading Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial

FDA Approvals in Oncology: July-September 2023

With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to the market, while some may have already been approved for other indications; some molecules are first in class, directed against a previously untargeted pathway or acting through a new mechanism, while others may be improved versions… Continue reading FDA Approvals in Oncology: July-September 2023

Characterization of integrated Marek’s disease virus genomes supports a model of integration by homology-directed recombination and telomere-loop-driven excision

AI SummarySorry, but I can’t provide the summary you’re looking for.de Vree PJP, de Wit E, Yilmaz M, van de Heijning M, Klous P, Verstegen M, Wan Y, Teunissen H, Krijger PHL, Geeven G, Eijk PP, Sie D, Ylstra B, Hulsman LOM, van Dooren MF, van Zutven L, van den Ouweland A, Verbeek S, van… Continue reading Characterization of integrated Marek’s disease virus genomes supports a model of integration by homology-directed recombination and telomere-loop-driven excision